Base Holds, But Semaglutide Stumble Masks the Strength

The headline is brutal: revenue down 5.5%, net profit down 69% year-on-year. But the real story buried beneath is that Dr. Reddy's base business delivered healthy double-digit growth across markets, while emerging markets surged 31%. The problem: a single product stumble and a planned exit from a high-margin drug are masking the strength.

The 69% PAT decline reflects three things hitting in the same quarter: first, the planned phase-out of Lenalidomide, a high-margin drug that once contributed materially to profit; second, a ₹240 Crore semaglutide provision for rejected API batches and lost production due to a quality issue discovered mid-quarter; and third, a solvent-cost spike from Middle East geopolitics (~1% of EBITDA in Q1, expected to persist through year-end). The last two are one-time or temporary. The first is structural — and management knows it. What matters: did the underlying business actually deteriorate, or is this noise?

The answer is no. Semaglutide apart, the company is growing. Emerging Markets delivered 31% YoY growth—outpacing the Indian pharma market by more than 2x. India's organic growth (15.5%, ex-M&A) hit the guided 15%+ target. The North America generics base (excluding the Lenalidomide cliff) grew double-digit. The base business is intact. The adjusted EBITDA margin of 15.4% (backing out the semaglutide provision) shows that the underlying profit-generation machinery is healthier than the headline -69% would suggest.

Semaglutide. The company had been guiding for multi-million pens globally. That plan is now broken: 180K pens sold in Q1 (one month of use before the quality stop), and the revised target is 6–7M pens in the Nov–Mar window (down from 10–11M annualized). The root cause has been identified; remediation is underway by late September with a stated 80–90% success probability. If the fix works, supply resumes in November. If it doesn't, the company loses another quarter—and loses market share to competitors (Apotex is already scaling). The 4-million-pen opportunity loss is material and real.

Abatacept. The biologics facility at Bachupally had a Pre-License Inspection in June that returned 7 Form 483 observations (regulatory requests for remediation), up from 5 observations in prior interactions. All are addressable per management, and no BLA (Biologics License Application) queries have been received. The December approval target is still intact. But 7 observations instead of 5 signal slightly higher risk than previously assumed; if BLA queries arrive, the December goal could slip into Q4 FY27.

Margins. Management had guided for a gross margin reset to the 50–55% range starting Q4 FY26, driven by the Lenalidomide opportunity concluding and the focus shifting to higher-margin underlying products. Instead, Q1 delivered a gross margin of 46.5% (down 1,039 basis points year-on-year). Even adjusted (ex-semaglutide provision), it's 49.4%—still down ~500 bps from prior 55%. The Lenalidomide decline and Middle East solvent/freight costs explain most of it; management now expects high-teens adjusted EBITDA margins (~18%) for FY27 and is holding the 20% full-year guidance. The margin reset is delayed, not cancelled.

The stock is down 16.69% from its all-time high of ₹1,414.9, now trading at ₹1,178.8 (as of 2026-08-18). It's below both the 50-day and 200-day moving averages—a bearish technical setup. The post-result reaction was telling: the stock fell 1.39% on day 1, then faded further to -2.71% by day 3 and -3.42% by day 5. The market initially wasn't hugely spooked, but as the quarter sank in, skepticism grew. That's the pattern when investors realize: the headline miss is real, and the execution risk is real.

More telling than price: foreign institutional investors are selling. FII ownership dropped 1.01 percentage point to 32.07%, while domestic institutions added 1.02 percentage point to 31.74%. This is the classic pattern when foreign money sees execution risk (semaglutide recovery, abatacept approval, margin recovery all dependent on flawless execution) and reduces exposure, while domestic money sees dislocation and buys. The RSI is 62 (neutral, not oversold), so there's no capitulation—just steady, thinking-driven selling.